Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 10

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
 the Note remained outstanding.                                                                         
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  vi.       Effective                                                                                                                                                                                             

11. DERIVATIVE LIABILITY

The
Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “ Derivatives and Hedging”
and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number
of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated
and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is
carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded
as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change.

The
Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 1,780,402

Derivative
liability consisted of the following:

SCHEDULE
OF DERIVATIVE LIABILITY

                              June                         September                 
                              30, 2025                     30, 2024                  
 ─────────────────────────────────────────────────────────────────────────────────────
  Lender                      $               800,000      $              802,337    
  Lender                                      200,000                     200,584    
  Lender                                      400,000                     -          
  Lender                                      320,020                     -          
  Lender                                       60,381                     -          
  Toal                        $             1,780,402      $              1,404,090  
  Derivative                  $             1,780,402      $              1,404,090  

12. STOCKHOLDERS’ EQUITY

The
stockholders’ equity section of the Company contains the following classes of capital stock as of June 30, 2025:

  Common                                                                                                 

With
respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast
that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On
any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock